Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation Research
Published in: Inflammation Research 12/2010

01-12-2010 | Original Research Paper

Efficacy of periprosthetic erythromycin delivery for wear debris-induced inflammation and osteolysis

Authors: Weiping Ren, Renwen Zhang, Monica Hawkins, Tong Shi, David C. Markel

Published in: Inflammation Research | Issue 12/2010

Login to get access

Abstract

Objectives

We have reported that oral erythromycin (EM) inhibits periprosthetic tissue inflammation in a group of patients with aseptic loosening. The purpose of this study was to assess the efficacy of local, periprosthetic EM delivery in a rat model.

Methods

Uncoated Ti pins were press-fit into the right tibia of fourteen Sprague–Dawley rats following an intramedullar injection of UHMWPE (ultra high molecular weight polyethylene) particles. Revision surgeries were performed 2 months after the primary surgery. EM was applied to the Peri-Apatite™ (PA) layer of the titanium (Ti) pins. The previously implanted Ti pins were withdrawn and replaced with Ti pins coated either with (n = 7) or without (n = 7) EM. The rats were killed 1 month after “revision surgery”. The EM efficacy was evaluated by (MicroCT) μCT and histology.

Results

μCT analysis showed that bone volume percentage (BV/TV) was significantly higher in the EM-treated group compared to the untreated group (p < 0.05). Histological analysis showed that EM treatment inhibits UHMWPE particle-induced periprosthetic tissue inflammation compared to the untreated group.

Conclusion

This study demonstrated that periprosthetic EM delivery reduced periprosthetic inflammation and improved the quality of surrounding bone.
Literature
1.
Berry DJ, Harmsen WS, Cabanela ME, Morrey BF. Twenty-five-year survivorship of two thousand consecutive primary charnley total hip replacements : factors affecting survivorship of acetabular and femoral components. J Bone Joint Surg Am. 2002;84:171–7.PubMed
2.
Keener JD, Callaghan JJ, Goetz DD, et al. Twenty-five-year results after Charnley total hip arthroplasty in patients less than fifty years old: a concise follow-up of a previous report. J Bone Joint Surg Am. 2003;85-A:1066–72.PubMed
3.
Fender D, Harper WM, Gregg PJ. Outcome of Charnley total hip replacement across a single health region in England: the results at five years from a regional hip register [see comments]. J Bone Joint Surg Br. 1999;81:577–81.CrossRefPubMed
4.
Ingham E, Fisher J. Biological reactions to wear debris in total joint replacement. Proc Inst Mech Eng [H]. 2000;214:21–37.
5.
Greenfield EM, Bi Y, Ragab AA, et al. The role of osteoclast differentiation in aseptic loosening. J Orthop Res. 2002;20:1–8.CrossRefPubMed
6.
Merkel KD, Erdmann JM, McHugh KP, et al. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol. 1999;154:203–10.PubMed
7.
Stea S, Visentin M, Granchi D, et al. Wear debris and cytokine production in the interface membrane of loosened prostheses. J Biomater Sci Polym Ed. 1999;10:247–57.CrossRefPubMed
8.
Maloney WJ, Smith RL, Schmalzried TP, et al. Isolation and characterization of wear particles generated in patients who have had failure of a hip arthroplasty without cement. J Bone Joint Surg Am. 1995;77:1301–10.PubMed
9.
Sethi RK, Neavyn MJ, Rubash HE, Shanbhag AS. Macrophage response to cross-linked and conventional UHMWPE. Biomaterials. 2003;24:2561–73.CrossRefPubMed
10.
11.
Schwarz EM. What potential biologic treatments are available for osteolysis? J Am Acad Orthop Surg. 2008;16(Suppl 1):S72–5.PubMed
12.
Pollice PF, Rosier RN, Looney RJ, et al. Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes: a potential treatment for aseptic loosening of total joint components. J Bone Joint Surg Am. 2001;83-A:1057–61.PubMed
13.
Childs LM, Goater JJ, O’Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res. 2001;16:338–47.CrossRefPubMed
14.
Yatsunami J, Hayashi S. Fourteen-membered ring macrolides as anti-angiogenic compounds. Anticancer Res. 2001;21:4253–8.PubMed
15.
Cervin A. The anti-inflammatory effect of erythromycin and its derivatives, with special reference to nasal polyposis and chronic sinusitis. Acta Otolaryngol. 2001;121:83–92.CrossRefPubMed
16.
Giamarellos-Bourboulis EJ. Macrolides beyond the conventional antimicrobials: a class of potent immunomodulators. Int J Antimicrob Agents. 2008;31:12–20.CrossRefPubMed
17.
Nagai H, Shishido H, Yoneda R, et al. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration. 1991;58:145–9.CrossRefPubMed
18.
19.
Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998;157:1829–32.PubMed
20.
Sakito O, Kadota J, Kohno S, et al. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration. 1996;63:42–8.CrossRefPubMed
21.
Dette GA, Knothe H, Kellner HM. Whole body tissue distribution of [14C]-erythromycin in the guinea pig. an autoradiographic study. Arzneimittelforschung. 1987;37:524–7.PubMed
22.
Cuffini AM, Tullio V, Cimino F, Carlone NA. Comparative effects of roxithromycin and erythromycin on cellular immune functions in vitro. 1. Uptake of 3H-macrolides by human macrophages. Microbios. 1989;57:167–78.PubMed
23.
Ren WP, Li XY, Chen BD, Wooley PH. Erythromycin inhibits wear debris-induced osteoclastogenesis by modulation of murine macrophage NFkB activity. J Orthop Res. 2004;22:21–9.CrossRefPubMed
24.
Ren WP, Bin W, Mayton L, Wooley PH. Erythromycin (EM) inhibits wear debris-induced inflammatory osteolysis in a murine model. J Orthop Res. 2006;24:280–90.CrossRefPubMed
25.
Ren W, Blasier R, Peng X, et al. Effect of oral erythromycin therapy in patients with aseptic loosening of joint prostheses. Bone. 2009;44:671–7.CrossRefPubMed
26.
Stephenson PK, Freeman MA, Revell PA, et al. The effect of hydroxyapatite coating on ingrowth of bone into cavities in an implant. J Arthroplasty. 1991;6:51–8.CrossRefPubMed
27.
Karabatsos B, Myerthall SL, Fornasier VL, et al. Osseointegration of hydroxyapatite porous-coated femoral implants in a canine model. Clin Orthop Relat Res. 2001;392:442–9.CrossRefPubMed
28.
Hansson U, Ryd L, Toksvig-Larsen S. A randomised RSA study of Peri-Apatite HA coating of a total knee prosthesis. Knee. 2008;15:211–6.CrossRefPubMed
29.
Zhang R, An Y, Toth CA, et al. Osteogenic protein-1 enhances osseointegration of titanium implants coated with peri-apatite in rabbit femoral defect. J Biomed Mater Res B Appl Biomater. 2004;71:408–13.CrossRefPubMed
30.
Zhang R, Xu D, Landeryou T, et al. Ectopic bone formation using osteogenic protein-1 carried by a solution precipitated hydroxyapatite. J Biomed Mater Res A. 2004;71:412–8.CrossRefPubMed
31.
Wooley PH, Morren R, Andary J, et al. Inflammatory responses to orthopaedic biomaterials in the murine air pouch. Biomaterials. 2002;23:517–26.CrossRefPubMed
32.
Ren WP, Yang S, Wooley PH. A novel murine model of orthopaedic wear debris-associated osteolysis. Scand J Rheumatol. 2004;33:349–57.CrossRefPubMed
33.
Allen M, Brett F, Millett P, Rushton N. The effects of particulate polyethylene at a weight-bearing bone-implant interface A study in rats. J Bone Joint Surg Br. 1996;78:32–7.PubMed
34.
Morawietz L, Classen RA, Schroder JH, et al. Proposal for a histopathological consensus classification of the periprosthetic interface membrane. J Clin Pathol. 2006;59:591–7.CrossRefPubMed
35.
al Saffar N, Revell PA. Pathology of the bone-implant interfaces. J Long Term Eff Med Implants. 1999;9:319–47.PubMed
36.
Jones LC, Frondoza C, Hungerford DS. Immunohistochemical evaluation of interface membranes from failed cemented and uncemented acetabular components. J Biomed Mater Res. 1999;48:889–98.CrossRefPubMed
37.
Yang SY, Ren W, Park Y, et al. Diverse cellular and apoptotic responses to variant shapes of UHMWPE particles in a murine model of inflammation. Biomaterials. 2002;23:3535–43.CrossRefPubMed
38.
Ginebra MP, Traykova T, Planell JA. Calcium phosphate cements as bone drug delivery systems: a review. J Control Release. 2006;113:102–10.CrossRefPubMed
39.
Naber CK. Future strategies for treating Staphylococcus aureus bloodstream infections. Clin Microbiol Infect. 2008;14(Suppl 2):26–34.CrossRefPubMed
40.
Stigter M, Bezemer J, De GK, Layrolle P. Incorporation of different antibiotics into carbonated hydroxyapatite coatings on titanium implants, release and antibiotic efficacy. J Control Release. 2004;99:127–37.CrossRefPubMed
41.
Stigter M, De GK, Layrolle P. Incorporation of tobramycin into biomimetic hydroxyapatite coating on titanium. Biomaterials. 2002;23:4143–53.CrossRefPubMed
Metadata
Title
Efficacy of periprosthetic erythromycin delivery for wear debris-induced inflammation and osteolysis
Authors
Weiping Ren
Renwen Zhang
Monica Hawkins
Tong Shi
David C. Markel
Publication date
01-12-2010
Publisher
SP Birkhäuser Verlag Basel
Published in
Inflammation Research / Issue 12/2010
Print ISSN: 1023-3830
Electronic ISSN: 1420-908X
DOI
https://doi.org/10.1007/s00011-010-0229-x

Other articles of this Issue 12/2010

Inflammation Research 12/2010 Go to the issue

Original Research Paper

Central and peripheral anti-inflammatory effects of maprotiline on carrageenan-induced paw edema in rats

Original Research Paper

Honokiol: an effective inhibitor of high-glucose-induced upregulation of inflammatory cytokine production in human renal mesangial cells

Original Research Paper

The effect of the expression of angiotensin II on extracellular matrix metalloproteinase inducer (EMMPRIN) in macrophages is mediated via the AT1/COX-2/PGE2 pathway

Original Research Paper

Exhaled 8-isoprostane in sarcoidosis: relation to superoxide anion production by bronchoalveolar lavage cells

Original Research Paper

Rebamipide inhibits tumor necrosis factor-α-induced interleukin-8 expression by suppressing the NF-κB signal pathway in human umbilical vein endothelial cells

Commentary

“Old drugs” for the treatment of rheumatoid arthritis: will the cholinergic anti-inflammatory pathway and anti-nociceptive pathway work?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits